Related content

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

By Beaver Julia A   Park Ben H  

Future Oncology, Vol. 8, Iss. 6, 2012-06 ,pp. : 651-657

Future Medicine

Access to resources Recommend Favorite

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

By Torrisi Rosalba  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 667-672

Springer Publishing Company

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Current Treatment Strategies

By Perez Edith   Baweja Mansoina  

Cancer Investigation, Vol. 26, Iss. 6, 2008-07 ,pp. : 545-552

Informa Healthcare

Access to resources Recommend Favorite

Treatment strategy for HER2-positive breast cancer

By Mukai Hirofumi  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 335-340

Springer Publishing Company

Access to resources Recommend Favorite

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

By Lobbezoo Dorien   Kampen Roel   Voogd Adri   Dercksen M.   den Berkmortel Franchette   Smilde Tineke   Wouw Agnes   Peters Frank   Riel Johanna   Peters Natascha   Boer Maaike   Borm George   Tjan-Heijnen Vivianne  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 507-514

Springer Publishing Company

Access to resources Recommend Favorite